Efficient and specific cardiac IK₁ inhibition by a new pentamidine analogue
- PMID: 23625347
- DOI: 10.1093/cvr/cvt103
Efficient and specific cardiac IK₁ inhibition by a new pentamidine analogue
Abstract
Aims: In excitable cells, KIR2.x ion-channel-carried inward rectifier current (IK₁) is thought to set the negative and stable resting membrane potential, and contributes to action potential repolarization. Loss- or gain-of-function mutations correlate with cardiac arrhythmias and pathological remodelling affects normal KIR2.x protein levels. No specific IK1 inhibitor is currently available for in vivo use, which severely hampers studies on the precise role of IK1 in normal cardiac physiology and pathophysiology. The diamine antiprotozoal drug pentamidine (P) acutely inhibits IK₁ by plugging the cytoplasmic pore region of the channel. We aim to develop more efficient and specific IK₁ inhibitors based on the P structure.
Methods and results: We analysed seven pentamidine analogues (PA-1 to PA-7) for IK₁ blocking potency at 200 nM using inside-out patches from KIR2.1 expressing HEK-293 cells. PA-6 showed the highest potency and was tested further. PA-6 blocked KIR2.x currents of human and mouse with low IC₅₀ values (12-15 nM). Modelling indicated that PA-6 had less electrostatic but more lipophilic interactions with the cytoplasmic channel pore than P, resulting in a higher channel affinity for PA-6 (ΔG -44.1 kJ/Mol) than for P (ΔG -31.7 kJ/Mol). The involvement of acidic amino acid residues E224 and E299 in drug-channel interaction was confirmed experimentally. PA-6 did not affect INav1.5, ICa-L, IKv4.3, IKv11.1, and IKv7.1/minK currents at 200 nM. PA-6 inhibited the inward (50 nM 40%; 100 nM 59%; 200 nM 77%) and outward (50 nM 40%; 100 nM 76%; 200 nM 100%) components of IK₁ in isolated canine adult-ventricular cardiomyocytes (CMs). PA-6 prolonged action potential duration of CMs by 8 (n = 9), 26 (n = 5), and 34% (n = 11) at 50, 100, and 200 nM, respectively. Unlike P, PA-6 had no effect on KIR2.1 channel expression at concentrations from 0.1 to 3 μM. However, PA-6 at 10 μM increased KIR2.1 expression levels. Also, PA-6 did not affect the maturation of hERG, except when applied at 10 μM.
Conclusion: PA-6 has higher efficiency and specificity to KIR2.x-mediated current than P, lengthens action potential duration, and does not affect channel trafficking at concentrations relevant for complete IK₁ block.
Keywords: Cardiomyocytes; Inward rectifier current; KIR2.1; KIR2.2; KIR2.3; Molecular modelling; Pentamidine; Structure activity relation; Trafficking.
Similar articles
-
PA-6 inhibits inward rectifier currents carried by V93I and D172N gain-of-function KIR2.1 channels, but increases channel protein expression.J Biomed Sci. 2017 Jul 15;24(1):44. doi: 10.1186/s12929-017-0352-x. J Biomed Sci. 2017. PMID: 28711067 Free PMC article.
-
The anti-protozoal drug pentamidine blocks KIR2.x-mediated inward rectifier current by entering the cytoplasmic pore region of the channel.Br J Pharmacol. 2010 Apr;159(7):1532-41. doi: 10.1111/j.1476-5381.2010.00658.x. Epub 2010 Feb 24. Br J Pharmacol. 2010. PMID: 20180941 Free PMC article.
-
Pharmacological inhibition of IK1 by PA-6 in isolated rat hearts affects ventricular repolarization and refractoriness.Physiol Rep. 2016 Apr;4(8):e12734. doi: 10.14814/phy2.12734. Physiol Rep. 2016. PMID: 27117805 Free PMC article.
-
Cardiac potassium inward rectifier Kir2: Review of structure, regulation, pharmacology, and arrhythmogenesis.Heart Rhythm. 2021 Aug;18(8):1423-1434. doi: 10.1016/j.hrthm.2021.04.008. Epub 2021 Apr 20. Heart Rhythm. 2021. PMID: 33857643 Free PMC article. Review.
-
Inhibition of cardiac inward rectifier currents by cationic amphiphilic drugs.Curr Mol Med. 2013 Sep;13(8):1284-98. doi: 10.2174/15665240113139990043. Curr Mol Med. 2013. PMID: 23448372 Review.
Cited by
-
The network of cardiac KIR2.1: its function, cellular regulation, electrical signaling, diseases and new drug avenues.Naunyn Schmiedebergs Arch Pharmacol. 2024 Apr 29. doi: 10.1007/s00210-024-03116-5. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38683369 Review.
-
Chronic Propafenone Application Increases Functional KIR2.1 Expression In Vitro.Pharmaceuticals (Basel). 2023 Mar 7;16(3):404. doi: 10.3390/ph16030404. Pharmaceuticals (Basel). 2023. PMID: 36986503 Free PMC article.
-
Kir2.1-mediated membrane potential promotes nutrient acquisition and inflammation through regulation of nutrient transporters.Nat Commun. 2022 Jun 21;13(1):3544. doi: 10.1038/s41467-022-31149-y. Nat Commun. 2022. PMID: 35729093 Free PMC article.
-
Quantitative Analysis of the Cytoskeleton's Role in Inward Rectifier K IR 2.1 Forward and Backward Trafficking.Front Physiol. 2022 Jan 25;12:812572. doi: 10.3389/fphys.2021.812572. eCollection 2021. Front Physiol. 2022. PMID: 35145427 Free PMC article.
-
Investigation of the Effects of the Short QT Syndrome D172N Kir2.1 Mutation on Ventricular Action Potential Profile Using Dynamic Clamp.Front Pharmacol. 2022 Jan 18;12:794620. doi: 10.3389/fphar.2021.794620. eCollection 2021. Front Pharmacol. 2022. PMID: 35115940 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous